Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes.

Paczesny S, Metzger J.

Proteomics Clin Appl. 2018 Oct 11:e1800145. doi: 10.1002/prca.201800145. [Epub ahead of print] Review.

PMID:
30307119
2.

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated.

Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C; GV12-02 Writing Committee on behalf of the CIBMTR® Graft-versus-Host Disease Working Committee.

Haematologica. 2018 Oct;103(10):1708-1719. doi: 10.3324/haematol.2017.182550. Epub 2018 Aug 3.

3.

From proteomics to discovery of first-in-class ST2 inhibitors active in vivo.

Ramadan AM, Daguindau E, Rech JC, Chinnaswamy K, Zhang J, Hura GL, Griesenauer B, Bolten Z, Robida A, Larsen M, Stuckey JA, Yang CY, Paczesny S.

JCI Insight. 2018 Jul 25;3(14). pii: 99208. doi: 10.1172/jci.insight.99208. [Epub ahead of print]

4.

Less cholesterol means better tumor killing for cytotoxic T9 cells.

Griesenauer B, Paczesny S.

J Exp Med. 2018 Jun 4;215(6):1505-1506. doi: 10.1084/jem.20180852. Epub 2018 May 15.

PMID:
29764914
5.

Introduction to a review series on emerging immunotherapies for hematologic diseases.

Paczesny S, Pavletic SZ, Bollard CM.

Blood. 2018 Jun 14;131(24):2617-2620. doi: 10.1182/blood-2018-04-840793. Epub 2018 May 4. Review.

6.

The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Ren HG, Adom D, Paczesny S.

Expert Rev Clin Immunol. 2018 May;14(5):389-404. doi: 10.1080/1744666X.2018.1463159. Epub 2018 Apr 19.

PMID:
29629613
7.

Biomarkers for posttransplantation outcomes.

Paczesny S.

Blood. 2018 May 17;131(20):2193-2204. doi: 10.1182/blood-2018-02-791509. Epub 2018 Apr 5. Review.

PMID:
29622549
8.

Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

Palam LR, Mali RS, Ramdas B, Srivatsan SN, Visconte V, Tiu RV, Vanhaesebroeck B, Roers A, Gerbaulet A, Xu M, Janga SC, Takemoto CM, Paczesny S, Kapur R.

JCI Insight. 2018 Feb 22;3(4). pii: 94679. doi: 10.1172/jci.insight.94679. [Epub ahead of print]

9.

Biomarkers in chronic graft-versus-host disease: quo vadis?

Wolff D, Greinix H, Lee SJ, Gooley T, Paczesny S, Pavletic S, Hakim F, Malard F, Jagasia M, Lawitschka A, Hansen JA, Pulanic D, Holler E, Dickinson A, Weissinger E, Edinger M, Sarantopoulos S, Schultz KR.

Bone Marrow Transplant. 2018 Jul;53(7):832-837. doi: 10.1038/s41409-018-0092-x. Epub 2018 Jan 24.

PMID:
29367715
10.

Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.

Du J, Flynn R, Paz K, Ren HG, Ogata Y, Zhang Q, Gafken PR, Storer BE, Roy NH, Burkhardt JK, Mathews W, Tolar J, Lee SJ, Blazar BR, Paczesny S.

Blood. 2018 Apr 12;131(15):1743-1754. doi: 10.1182/blood-2017-08-800623. Epub 2018 Jan 18.

PMID:
29348127
11.

Neonatal hyperoxia promotes asthma-like features through IL-33-dependent ILC2 responses.

Cheon IS, Son YM, Jiang L, Goplen NP, Kaplan MH, Limper AH, Kita H, Paczesny S, Prakash YS, Tepper R, Ahlfeld SK, Sun J.

J Allergy Clin Immunol. 2018 Oct;142(4):1100-1112. doi: 10.1016/j.jaci.2017.11.025. Epub 2017 Dec 15.

PMID:
29253513
12.

Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation.

Seo S, Yu J, Jenkins IC, Leisenring WM, Steven-Ayers T, Kuypers JM, Huang ML, Jerome KR, Boeckh M, Paczesny S.

Biol Blood Marrow Transplant. 2018 Apr;24(4):678-686. doi: 10.1016/j.bbmt.2017.11.039. Epub 2017 Dec 6.

PMID:
29223372
13.

Specifically differentiated T cell subset promotes tumor immunity over fatal immunity.

Ramadan A, Griesenauer B, Adom D, Kapur R, Hanenberg H, Liu C, Kaplan MH, Paczesny S.

J Exp Med. 2017 Dec 4;214(12):3577-3596. doi: 10.1084/jem.20170041. Epub 2017 Oct 16.

14.

Editorial: Danger Signals Triggering Immune Response and Inflammation.

Ramadan A, Land WG, Paczesny S.

Front Immunol. 2017 Aug 11;8:979. doi: 10.3389/fimmu.2017.00979. eCollection 2017. No abstract available.

15.

Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.

Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, Farag S, Paczesny S, Konig H.

Int J Mol Sci. 2017 Jul 31;18(8). pii: E1660. doi: 10.3390/ijms18081660. Review.

16.

Acute Graft-Versus-Host Disease Prognosis: Are Biomarkers Ready for Preemptive Clinical Trials?

Paczesny S.

Clin Chem. 2017 Oct;63(10):1561-1563. doi: 10.1373/clinchem.2017.272872. Epub 2017 Jul 7. No abstract available.

17.

An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR.

JCI Insight. 2017 Jun 15;2(12). pii: 92111. doi: 10.1172/jci.insight.92111. [Epub ahead of print]

18.

The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases.

Griesenauer B, Paczesny S.

Front Immunol. 2017 Apr 24;8:475. doi: 10.3389/fimmu.2017.00475. eCollection 2017. Review.

19.

B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.

Saliba RM, Sarantopoulos S, Kitko CL, Pawarode A, Goldstein SC, Magenau J, Alousi AM, Churay T, Justman H, Paczesny S, Reddy P, Couriel DR.

Bone Marrow Transplant. 2017 Jul;52(7):1010-1015. doi: 10.1038/bmt.2017.73. Epub 2017 May 8.

20.

Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.

Inamoto Y, Martin PJ, Paczesny S, Tabellini L, Momin AA, Mumaw CL, Flowers MED, Lee SJ, Carpenter PA, Storer BE, Hanash S, Hansen JA.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1250-1256. doi: 10.1016/j.bbmt.2017.04.019. Epub 2017 Apr 25.

21.

Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.

Kanakry CG, Bakoyannis G, Perkins SM, McCurdy SR, Vulic A, Warren EH, Daguindau E, Olmsted T, Mumaw C, Towlerton AMH, Cooke KR, O'Donnell PV, Symons HJ, Paczesny S, Luznik L.

Haematologica. 2017 May;102(5):932-940. doi: 10.3324/haematol.2016.152322. Epub 2017 Jan 25.

22.

Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling.

Johnpulle RA, Paczesny S, Jung DK, Daguindau E, Jagasia MH, Savani BN, Chinratanalab W, Cornell RF, Goodman S, Greer JP, Kassim AA, Sengsayadeth S, Byrne MT, Engelhardt BG.

Biol Blood Marrow Transplant. 2017 Mar;23(3):529-532. doi: 10.1016/j.bbmt.2016.12.627. Epub 2016 Dec 21.

23.

Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.

Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S, Choi SW.

Blood. 2017 Jan 12;129(2):162-170. doi: 10.1182/blood-2016-08-735324. Epub 2016 Nov 8.

24.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Gea-Banacloche J, Komanduri KV, Carpenter P, Paczesny S, Sarantopoulos S, Young JA, El Kassar N, Le RQ, Schultz KR, Griffith LM, Savani BN, Wingard JR.

Biol Blood Marrow Transplant. 2017 Jun;23(6):870-881. doi: 10.1016/j.bbmt.2016.10.001. Epub 2016 Oct 14. Review.

25.

The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, van den Brink MRM, Hansen JA, Parkman R, Miklos DB, Martin PJ, Paczesny S, Vogelsang G, Pavletic S, Ritz J, Schultz KR, Blazar BR.

Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. doi: 10.1016/j.bbmt.2016.09.023. Epub 2016 Oct 3. Review.

26.

JAK polymorphisms: jack of all cytokines, masters GVHD?

Kushekhar K, Paczesny S.

Leuk Lymphoma. 2017 Feb;58(2):255-256. Epub 2016 Aug 9. No abstract available.

PMID:
27685636
27.

Improved reproducibility and quality of GvHD biomarker assay: application of multiplex microfluidic channel system.

Anandi P, Tian X, Chinian F, Cantilena CR, Dunavin N, Hensel N, Draper D, Koklanaris E, Maxwell S, Superata J, Muranski P, Battiwalla M, Paczesny S, Barrett AJ, Ito S.

Bone Marrow Transplant. 2016 Dec;51(12):1615-1616. doi: 10.1038/bmt.2016.226. Epub 2016 Sep 5. No abstract available.

PMID:
27595279
28.

CXCL10: most consistent cGVHD biomarker?

Paczesny S, Abu Zaid M.

Blood. 2016 Jun 16;127(24):2950-1. doi: 10.1182/blood-2016-04-709543. No abstract available.

29.

Biomarker Panel for Chronic Graft-Versus-Host Disease.

Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, Ogata Y, Martin PJ, Flowers ME, Hansen JA, Arora M, Cutler C, Jagasia M, Pidala J, Hamilton BK, Chen GL, Pusic I, Lee SJ, Paczesny S.

J Clin Oncol. 2016 Aug 1;34(22):2583-90. doi: 10.1200/JCO.2015.65.9615. Epub 2016 May 23.

30.

Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.

Li W, Liu L, Gomez A, Zhang J, Ramadan A, Zhang Q, Choi SW, Zhang P, Greenson JK, Liu C, Jiang D, Virts E, Kelich SL, Chu HW, Flynn R, Blazar BR, Hanenberg H, Hanash S, Paczesny S.

JCI Insight. 2016 May 5;1(6). pii: e86660.

31.

Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation.

Liu X, Yue Z, Yu J, Daguindau E, Kushekhar K, Zhang Q, Ogata Y, Gafken PR, Inamoto Y, Gracon A, Wilkes DS, Hansen JA, Lee SJ, Chen JY, Paczesny S.

Am J Transplant. 2016 Aug;16(8):2342-51. doi: 10.1111/ajt.13750. Epub 2016 Mar 14.

32.

Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation.

Engelhardt BG, Paczesny S, Jung DK, Daguindau E, Jagasia M, Savani BN, Chinratanalab W, Cornell RF, Goodman S, Greer JP, Kassim AA, Sengsayadeth S, Yoder SM, Rock MT, Crowe JE Jr.

Haematologica. 2016 May;101(5):e204-8. doi: 10.3324/haematol.2015.139501. Epub 2016 Jan 27. No abstract available.

33.

SNPs and prognosis of GvHD before HCT: any progress?

Abu Zaid MI, Paczesny S, Miklos DB.

Bone Marrow Transplant. 2016 Feb;51(2):161-2. doi: 10.1038/bmt.2015.240. Epub 2015 Oct 12. No abstract available.

PMID:
26457906
34.

ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.

Zhang J, Ramadan AM, Griesenauer B, Li W, Turner MJ, Liu C, Kapur R, Hanenberg H, Blazar BR, Tawara I, Paczesny S.

Sci Transl Med. 2015 Oct 7;7(308):308ra160. doi: 10.1126/scitranslmed.aab0166.

35.

Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.

Akil A, Zhang Q, Mumaw CL, Raiker N, Yu J, Velez de Mendizabal N, Haneline LS, Robertson KA, Skiles J, Diaz-Ricart M, Carreras E, Renbarger J, Hanash S, Bies RR, Paczesny S.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1739-45. doi: 10.1016/j.bbmt.2015.07.004. Epub 2015 Jul 11.

36.

Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.

Ramadan A, Paczesny S.

Front Immunol. 2015 Jan 28;6:14. doi: 10.3389/fimmu.2015.00014. eCollection 2015. Review.

37.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Paczesny S, Hakim FT, Pidala J, Cooke KR, Lathrop J, Griffith LM, Hansen J, Jagasia M, Miklos D, Pavletic S, Parkman R, Russek-Cohen E, Flowers ME, Lee S, Martin P, Vogelsang G, Walton M, Schultz KR.

Biol Blood Marrow Transplant. 2015 May;21(5):780-92. doi: 10.1016/j.bbmt.2015.01.003. Epub 2015 Jan 30.

38.

Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes.

Gleimer M, Li Y, Chang L, Paczesny S, Hanauer DA, Frame DG, Byersdorfer CA, Reddy PR, Braun TM, Choi SW.

Bone Marrow Transplant. 2015 Mar;50(3):402-10. doi: 10.1038/bmt.2014.280. Epub 2014 Dec 22.

39.

High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.

Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S, Goldberg JD, Hanash A, Hsu K, Jenq R, Perales MA, Sauter C, van den Brink MR, Young JW, Brentjens R, Kernan NA, Prockop SE, O'Reilly RJ, Scaradavou A, Paczesny S, Barker JN.

Blood. 2015 Jan 1;125(1):199-205. doi: 10.1182/blood-2014-06-584789. Epub 2014 Nov 6.

40.

Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.

Paczesny S, Duncan C, Jacobsohn D, Krance R, Leung K, Carpenter P, Bollard C, Renbarger J, Cooke K.

Proteomics Clin Appl. 2014 Dec;8(11-12):837-50. doi: 10.1002/prca.201400033. Epub 2014 Oct 30. Review.

41.

Aqueous two-phase systems enable multiplexing of homogeneous immunoassays.

Simon AB, Frampton JP, Huang NT, Kurabayashi K, Paczesny S, Takayama S.

Technology (Singap World Sci). 2014 Jun;2(2):176.

42.

Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation.

Nelson RP Jr, Khawaja MR, Perkins SM, Elmore L, Mumaw CL, Orschell C, Paczesny S.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1861-4. doi: 10.1016/j.bbmt.2014.06.039. Epub 2014 Jul 10.

43.

Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Gatza E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DR, Goldstein S, Connelly J, Reddy P, Paczesny S, Choi SW.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1426-34. doi: 10.1016/j.bbmt.2014.05.023. Epub 2014 Jun 2.

44.

Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Chang L, Frame D, Braun T, Gatza E, Hanauer DA, Zhao S, Magenau JM, Schultz K, Tokala H, Ferrara JL, Levine JE, Reddy P, Paczesny S, Choi SW.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1407-17. doi: 10.1016/j.bbmt.2014.05.022. Epub 2014 Jun 2.

45.

Aqueous two-phase system patterning of detection antibody solutions for cross-reaction-free multiplex ELISA.

Frampton JP, White JB, Simon AB, Tsuei M, Paczesny S, Takayama S.

Sci Rep. 2014 May 2;4:4878. doi: 10.1038/srep04878.

46.

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, Couriel DR, Martin PJ, Flowers ME, Hansen JA, Chang L, Conlon M, Fiema BJ, Morgan R, Pongtornpipat P, Lamiman K, Ferrara JL, Lee SJ, Paczesny S.

Blood. 2014 Jan 30;123(5):786-93. doi: 10.1182/blood-2013-08-520072. Epub 2013 Dec 20.

47.

Biomarkers for fatal immune response to stem cell treatment could reduce mortality.

Paczesny S.

Biomark Med. 2014;8(1):65-8. doi: 10.2217/bmm.13.113. No abstract available.

48.

Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.

Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P.

Lancet Oncol. 2014 Jan;15(1):87-95. doi: 10.1016/S1470-2045(13)70512-6. Epub 2013 Nov 30.

49.

Graft-versus-host disease biomarkers: omics and personalized medicine.

Paczesny S, Raiker N, Brooks S, Mumaw C.

Int J Hematol. 2013 Sep;98(3):275-92. Review.

50.

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S.

N Engl J Med. 2013 Aug 8;369(6):529-39. doi: 10.1056/NEJMoa1213299.

Supplemental Content

Loading ...
Support Center